

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 8-K

DUSA PHARMACEUTICALS INC

Form 8-K

April 01, 2003

FORM 8-K

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2003

DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

NEW JERSEY
(State or other
jurisdiction of
incorporation)

0-19777
(Commission
File Number)

22-3103129
(IRS Employer
Identification
Number)

25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)

(978) 657-7500
(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS.

DUSA Pharmaceuticals, Inc. ("DUSA") issued a press release on March 31, 2003, attached to and made part of this report, noting the interest in its product, Levulan(R) Photodynamic Therapy ("PDT"), at the annual meeting of the American Academy of Dermatology which took place in San Francisco on March 21-27, 2003.

Except for historical information, this report, including the exhibit, contains a forward-looking statement that involves known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statement made. This forward-looking statement relates to the belief that interest in Levulan PDT(R) shown at the AAD will positively impact sales revenues. The statement is qualified by factors, including, without limitation, the impact of competitive products, reimbursement by third-party payors, sales and marketing efforts, maintenance of our patent portfolio and other risks identified in DUSA's SEC filings from time to time, including our recently filed Form 10-K for the year ended December 31, 2002.

ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS.

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 8-K

(c) Exhibits.

[99] Press Release dated March 31, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DUSA PHARMACEUTICALS, INC.

Dated: March 31, 2003

By: /s/ D. Geoffrey Shulman

D. Geoffrey Shulman, MD, FRCPC
President, Chief Executive Officer